DaVita HealthCare (DVA) Rises Higher Than Market: Key Facts

DaVita HealthCare (DVA) recently closed up 1.75%, outperforming the S&P 500, following a 5.2% decline over the past month. The kidney dialysis provider is anticipated to report robust growth, with the upcoming quarter's EPS projected to increase by 27.03% and revenue by 4.27% year-over-year. DVA holds a favorable Zacks Rank #2 (Buy) and exhibits attractive valuation metrics, including a Forward P/E of 11.95 and a PEG ratio of 0.94, both trading at a significant discount to its industry averages.

Analysis

DaVita HealthCare (DVA) demonstrated a single-day outperformance of the broader market with a 1.75% gain, though this follows a period of underperformance where the stock declined 5.2% over the past month against the S&P 500's 3.15% gain. The near-term outlook is driven by upcoming earnings, with consensus estimates pointing to significant growth: a 27.03% year-over-year increase in EPS to $3.29 and a 4.27% rise in revenue to $3.4 billion. Full-year projections support this positive trend, forecasting 12.91% earnings growth and 5.01% revenue growth. The stock's valuation appears compelling, with a forward P/E ratio of 11.95 and a PEG ratio of 0.94, both representing a significant discount to its industry averages of 21.36 and 1.96, respectively. This undervaluation is further supported by a Zacks Rank of #2 (Buy) and the company's position within a highly-ranked industry (top 17%), though it is notable that analyst EPS estimates have not seen any revisions over the past month.

Key Decisions for Investors

• Consider DVA as a potential growth-at-a-reasonable-price (GARP) opportunity, given its projected 27.03% quarterly EPS growth is paired with a PEG ratio of 0.94, which indicates a significant discount relative to its growth profile and industry peers.
• Investors should closely monitor the upcoming earnings release to validate the strong consensus growth estimates, as this event will be a critical catalyst for a stock that has underperformed the market over the last month.
• Despite the Zacks #2 (Buy) rating, the lack of recent upward revisions to analyst estimates suggests that a significant earnings beat, rather than just meeting expectations, may be necessary to drive substantial near-term share price appreciation.